Questions & Answers
Introduction:
This Question and answers section gives advice on regulatory issues in connection with the Mutual Recognition and Decentralised Procedures. Reference is made, where additional information is available from CMDh guidance documents.
For general regulatory guidance on the interpretation and implementation of the new pharmaceutical legislation, please refer to the Notice to Applicants, where updated guidance will be published by the European Commission.
https://ec.europa.eu/health/documents/eudralex/vol-2_en
Index Questions & Answers:
- Active Substance Master File [Track version] (November 2022)
Advice from CMDh [Track version] (September 2014)
- Applications for MA [Track version] (April 2017)
- Biologicals (October 2025) [Track version]
- CMDh Referrals [Track version] (February 2016)
- EU enlargement [Track version] (December 2012)
- Generics (October 2025) [Track version]
- Homeopathic medicinal products [Track version] November 2019
- Paediatric Regulation [Track version] (February 2025)
Further Q&As have been published on the EMA website
- Pharmacovigilance Legislation (October 2025) [Track version]
- Post-Authorisation Efficacy Studies (PAES) in MRP/DCP(November 2015)
- Post-Brexit (October 2025)
- Post referral phase [Track version] (March 2017)
- Product Information/Information on Medicinal Products [Track version] (October 2017)
- QP declaration [Track version] (February 2025)
- Renewals [Track version] (April 2023)
- Traditional Herbal Medicinal Products [Track version] (March 2013)
- Usage Patents (May 2019) [Track version]
- Variations (October 2025, correction January 2026) [Track version]
